Vijaya R Bhatt1, Smith Giri2, Vivek Verma1, Sumit Dahal3, Binay K Shah4, Ranjan Pathak5, R Gregory Bociek1, Julie M Vose1, James O Armitage1. 1. Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, NE 68198, USA. 2. Department of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA. 3. Department of Internal Medicine, Interfaith Hospital, 1545 Atlantic Avenue, Brooklyn, NY 11213, USA. 4. Divison of Hematology & Oncology, St Joseph Regional Medical Center, 415 Sixth St., Lewiston, ID 83501, USA. 5. Department of Medicine, Reading Health System, Sixth Avenue and Spruce Street, Reading, PA 19612, USA.
Abstract
BACKGROUND: This large population-based study determined the epidemiology and outcomes of secondary acute myeloid leukemia (sAML) developing in Hodgkin lymphoma survivors. METHODS: We utilized the Surveillance Epidemiology and End Results (SEER) 9 database to identify 104 cases of sAML. RESULTS: Patients with sAML (median age: 47 years; 82% <60 years) were significantly younger than de novo AML cases (66 years; p < 0.01). sAML had worse overall survival (OS) than de novo AML (p < 0.01). OS was better in younger patients and in more recent years. CONCLUSION: Older patients with sAML have a dismal OS and should be enrolled in trials of novel therapies. Younger patients have improved OS and hence may benefit from curative intent intensive therapy and allogeneic transplant.
BACKGROUND: This large population-based study determined the epidemiology and outcomes of secondary acute myeloid leukemia (sAML) developing in Hodgkin lymphoma survivors. METHODS: We utilized the Surveillance Epidemiology and End Results (SEER) 9 database to identify 104 cases of sAML. RESULTS:Patients with sAML (median age: 47 years; 82% <60 years) were significantly younger than de novo AML cases (66 years; p < 0.01). sAML had worse overall survival (OS) than de novo AML (p < 0.01). OS was better in younger patients and in more recent years. CONCLUSION: Older patients with sAML have a dismal OS and should be enrolled in trials of novel therapies. Younger patients have improved OS and hence may benefit from curative intent intensive therapy and allogeneic transplant.